Navigation Links
One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High

Survey Reveals Five Ways a Woman Can Work With Her Doctor to Manage

Menopausal Symptoms

WASHINGTON, Sept. 5 /PRNewswire/ -- Results from one of the largest national surveys of doctors involved in menopause care conducted since the release of initial findings from the Women's Health Initiative (WHI) leave no doubt -- even five years later, a cloud of confusion lingers for both physicians and patients regarding the results of the WHI study. The online survey of over 400 physicians concludes that patients remain confused about the risks of hormone therapy (HT); in fact, only 15% of doctors believe their patients accurately perceive the risks of HT. The survey was conducted by Richard Day Research on behalf of The Hormone Foundation, with the support of Novogyne Pharmaceuticals.

Amongst the key findings of the survey is that only 18 percent of physicians have "no confusion at all" about the WHI findings. However, physicians feel the confusion that exists among the general public is much greater:

-- 93% feel the level of misinformation patients bring to their office

about the WHI findings has "somewhat" or "very much" affected their


-- More than two-thirds feel their patients and the media have "a great

deal of confusion" now about the WHI findings

-- 83% of doctors report their patients are as or more confused now than

when the findings were first released in 2002

-- 81% of doctors believe the media are as or more confused now than when

the findings were first released

"Since the results of the WHI were first released in 2002, the public has been bombarded with conflicting information on how to interpret the findings," said Paula Correa, MA, Director of The Hormone Foundation. "The results of this survey underscore the importance of physicians' role in educating patients and calls for more public education on menopause management. This is a complex issue and patients should participate in a continuous open dialogue with their physicians to arrive at treatment decisions best for their individual needs."

Physicians make treatment decisions based on information shared by their patients. The survey revealed that 100 percent of physicians say the severity of their patients' symptoms is "somewhat" or "very important" to them when deciding whether to prescribe HT, closely followed by the range and specific types of symptoms (97 percent) and patient requests (94 percent).

Doctors were also asked to choose from a list of valuable tips to help their patients manage menopause. The following were the top five selections:

#1: Document and prioritize their symptoms, including how often they have

symptoms and how severe they are

#2: Think through your own risk/benefit comfort level prior to a


#3: Come to the physician's office with a list of questions prepared

#4: Learn about HT in general ahead of time

#5: Document your family health history

"In some ways, the complexity of the WHI has been a blessing in disguise," said menopause expert Nanette Santoro, MD, Professor and Director of the Albert Einstein College of Medicine/Montefiore Medical Center's Division of Reproductive Endocrinology in New York and member of The Hormone Foundation's Women's Health Task Force. "Physicians are spending more time than ever discussing the risks and benefits of HT with their patients and are focused on individualizing the HT regimen to the specific needs of the patient. This can include adjusting the amount of the dose, the ingredients and the route of administration."

The survey showed that for the treatment of moderate to severe menopause symptoms, 74 percent of physicians still think of HT as a first line treatment. In addition, the survey identified that physicians are considering HT options outside of the traditional pill formulations more often: in the last two years, 43 percent of physicians have prescribed non-oral HT "somewhat" or "a lot more often" for their patients, with 71 percent saying their patients preferred the transdermal patch over other non-oral options.

The survey also dug deeper into how the WHI findings have affected menopause management practices in several different areas including:

-- How physicians from different specialties, who self-identify as

menopause specialists, understand the WHI and view the risks and

benefits of HT differently than those who do not

-- When, for how long and what type of HT to prescribe

-- Referral rates to physicians more experienced in menopause management

-- What information they discuss with patients and in what detail

-- Information needs and educational tools desired for themselves and

their patients

To view the full survey responses, please visit . To arrange an interview with a menopause expert regarding the survey findings, please contact Jocelyn Jara at 305-573-9955 or 786-554-6032, for interview coordination.

About the Survey

The results of this study are based on a survey of 404 physicians who are involved in menopause management, including the following primary medical specialties: endocrinologists, obstetrician/gynecologists, internal medicine, family or general practitioners. The maximum margin of error (at the 95 percent confidence level) for a sample of 404, assuming no bias, is +/- 5 percent. The survey was conducted between April 16 and May 23, 2007, by Richard Day Research of Evanston, IL. Physicians completed the survey online. Physicians were drawn from a national list of physicians involved in menopause care and Endocrine Society members. Final data were weighted to reflect the population of all physicians involved in menopause care.

To qualify for the survey, a physician had to devote at least 70% of their working day to clinical practice, see at least two patients with menopausal symptoms in a typical month and treat patients for at least six years post-residency or fellowship.

About The Hormone Foundation

The Hormone Foundation, the public education affiliate of The Endocrine Society, is a leading source of hormone-related health information for the public, physicians, allied health professionals and the media. Its mission is to serve as a resource for the public by promoting the prevention, treatment and cure of hormone-related conditions through outreach and education. For more information about The Hormone Foundation, please visit

About Novogyne Pharmaceuticals

Novogyne Pharmaceuticals is a joint venture between Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, and Noven Pharmaceuticals, Inc. of Miami, Florida. Since May 1998, Novogyne has been offering pharmaceutical products that enable physicians to better serve the medical needs of mature women. Novogyne was the first company in the U.S. offering transdermal systems for both the estrogen-only and combination estrogen/progestin markets. For more information about Novogyne Pharmaceuticals and its products, please visit

SOURCE The Hormone Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. 3 die, 500 sickened in nations largest hepatitis A outbreak Associated Press
2. Worlds Largest Cord Blood Bank to be started in India
3. India Has The Oldest And Largest Collection Of Preserved Mosquitoes – Mosquito Museu
4. Heart Related Problems-The Largest Killers In Andhra Pradesh
5. Children’s Center to Lead Largest-Ever Study on Kidney Disease in Childre
6. Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date
7. Missed Vaccination Caused Largest Measles Outbreak in U.S in 2005
8. Largest Ever African HIV Vaccine Trial Opens in South Africa
9. Primary Health Care Parishioners of Second Largest HIV Infected Area in US Fail to Offer HIV Tests
10. World Largest Hair Congress Convene in Vancouver
11. Largest Ever Study of Genetics Behind Common Diseases Published
Post Your Comments:
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... ... to six decades of music, friendships, and learning in its 65th Anniversary Brillianteen ... held Dec. 5-6. , For 65 years, Brillianteen has been a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 - Will Also ... (CME) --> - Will ... Education (CME) --> - Will ... Continuing Medical Education (CME) Elsevier , ... services, will feature latest diagnostic imaging textbooks and decision support tools, ...
(Date:11/24/2015)... 25, 2015 The hope of ... failure of IVF cycles. After failure of over 15 ... had lost all hopes that she would be able to conceive ever. But finally optimism ... conceived after failure of over 15 IVF cycles. ... they decided to take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
Breaking Medicine Technology: